In the present study, a series of 6-bromo-2,3-disubstitued-4(3H) 
anticancer, 13) MAO inhibitory 14) and central nervous system activities. 15) 4(3H)-Quinazolinones with 3-substitution has been reported to be associated with antimicrobial properties. [16] [17] [18] The 3-substitution which were reported are various substituted phenyl ring moieties, 19) bridged phenyl rings, 20) heterocyclic rings [21] [22] [23] and aliphatic systems. 24) 2,3-Substituted-4(3H)-quinazolinones 25) were reported to possess antimicrobial properties. The antibacterial, antifungal and anti-HIV screening of semi-derivatized conventional antibacterial agents namely trimethoprim, 26, 27) sulphadoxime, 28, 29) norfloxacin, 30, 31) ciprofloxacin 32) and lomefloxacin 32) have been reported.
These observation lead to the conception that a new series of 2-methyl/2-phenyl-4(3H)-quinazolinones with 2,4-diaminopyrimidine (trimethoprim and pyrimethamine) and 3,5-diaminotriazine (lamotrigine) substitutent in 3rd position would exhibit potential cytoprotective and antiviral activity. The 2,4-diaminopyrimidines selected for the study possess dihydro folate reductase inhibitory property. Triazines 33) have been reported to exhibit dihydro folate reductase inhibitory property. In continuation of our earlier work 34) on 4(3H)-quinazolinones, the present study deals with the synthesis of a series of 6-bromo-2,3-disubstitued-4(3H)-quinazolinones by condensation of 6-bromo-2-substituted-benzoxazin-4-one with trimethoprim, pyrimethamine and lamotrigine. The chemical structures of the synthesized compounds were confirmed by means of IR, 1 H-NMR, mass spectral and elemental analysis. The antiviral activity and cytotoxicity of the compounds were tested in E 6 SM (Herpes simplex-1 KOS, Chemistry The melting points were taken in open capillary tube on a Thomas Hoover melting point apparatus and are uncorrected. The IR spectra of the compounds were recorded on Bruker Vector-22 FT-IR with KBr pellets.
1 H-NMR spectra were recorded on 500 MHz Bruker AMX 500 using DMSO-d 6 as solvent. The chemical shifts are reported as parts per million downfield from tetramethylsilane (Me 4 Si). Mass spectra were recorded on Varian Atlas CH-7. Microanalyses for C, H, N were performed in Heraeus CHN Rapid Analyzer. All the compounds gave satisfactory chemical analyses (Ϯ0.4%). The purity of the compounds were checked by TLC on SiO 2 gel (HF 254 , 200 mesh) coated glass plates using (4 : 1) CH 3 OH : CHCl 3 as mobile phase and visualized by iodine vapours.
Synthesis of 2-Methyl-6-bromo-3,1-benzoxazin-4-one A mixture of 5-bromoanthranilic acid (0.1 mol) and acetic anhydride (0.2 mol) was refluxed under anhydrous conditions for 4 h. The excess acetic anhydride was distilled off under reduced pressure. The product formed was filtered, vacuum dried and recrystallised using absolute ethanol. Yieldϭ58%, mp 180-181°C. 1 General Procedure for 6-Bromo-2,3-disubstituted-4(3H)-quinazolinones Equimolar quantities (0.01 mol) of 6-bromo-2-substituted-3,1-benzoxazin-4-one and the primary amine (trimethoprim, pyrimethamine and lamotrigine) in glacial acetic acid (10 ml) was refluxed for 6 h. The reaction content was cooled to room temperature and poured into crushed ice. The product formed was filtered, vacuum dried and recrystallised using absolute ethanol ( Fig. 1) . Antiviral Activity and Cytoxicity The antiviral activity and cytotoxicity [35] [36] [37] [38] [39] of the synthesized compounds were to reduce virus-induced cytopathogenicity by 50% were recorded. The antiviral and cytotoxicity data are presented in Table 1 and 2. Anti-HIV Activity Cell Cultures: The MT-4 cells were grown in RPM1-1640 DM ("Dutch Modification") medium (Flow Laboratories, Irvine, Scotland), supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) and 20 mg/ml gentamicin (E. Merck, Darmstadt, F.R.G.). The cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 in air. Every 3-4 d, cells were spun down and seeded at 3ϫ10 5 cells/ml in new cell culture flasks. At regular intervals, the MT-4 cells were analyzed for the presence of mycoplasma and consistently found to be mycoplasmafree.
Virus: HIV-1 (strain HTLV-IIIB LAI) 40) was obtained from the culture supernatant of HIV-1 infected MT-4 cell lines. 41) The Virus titer of the supernatant was determined in MT-4 cells. The virus stocks were stored at Ϫ70°C until used.
Anti-HIV Assay: Flat bottom, 96-well plastic microtiter plates (Falcon, Becton Dickinson, Mountain view, CA, U.S.A.) were filled with 100 ml of complete medium using a Titertek multidrop dispenser (Flow Laboratories). This eight channel dispenser could fill a microtiter tray in less than 10 s. Subsequently, stock solutions (10ϫ final test concentration) of compounds were added in 25 ml volumes to two series of triplicate wells so as to allow simultaneous evaluation of their effects on HIV-and mock-infected cells. Serial five-fold dilutions were made directly in the microtiter trays using a Biomek 1000 robot (Beckman). Untreated control HIV-and mock-infected cell samples was included for each compound. 50 ml of HIV at 100 CCID 50 medium was added to either infected or mock-infected part of a microtiter tray. Exponentially growing MT-4 cells were centrifuged for 5 min at 140ϫg and the supernatants were discarded. The MT-4 cells resuspended at 6ϫ10 5 cells/ml in a flask that was connected with an autoclavable dispensing cassette of Titertek multidrop dispenser. Under slight magnetic stirring 50 ml volumes were then transferred to the microtiter tray wells. The outer row wells were filled with 200 ml of medium. The cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air. The cells remained in contact with the test compounds during the whole incubation period. Five days after infection, the viability of mock and HIV-infected cells were examined spectrophotometrically by the MTT method.
MTT Assay: The MTT assay was based on the reduction of the yellow colored 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemical Co., St. Louis, MO, U.S.A.) by mitochondrial dehydrogenase of metabolically active cells to a blue formazan which can be measured spectrophotometrically. Therefore, to each well of the microtiter plates 20 ml of a solution of MTT (7.5 mg/ml) in phosphate-buffered saline was added using the Titertek Multidrop. The trays were further incubated at 37°C in a CO 2 incubator for one hour. A fixed volume of medium (150 ml) was then removed from each cup using M96 washer (ICN flow) without disturbing the MT-4 cells clusters containing the formazan crystals. Solubilization of the formazan crystals was achieved by adding 100 ml of 10% (v/v) Triton X-100 in acidified isopropanol (2 ml concentrated HCI per 500 ml solvent) using the M96 washer. Complete dissolution of the formazan crystals could be obtained after the trays had been placed on a plate shaker for 10 min. Finally, the absorbances were read in a eight-channel computer-controlled photometer (Multiskan MCC, ICN flow) at two wavelengths (540, 690 nm). The absorbance measured at 690 nm was automatically subtracted from the absorbance at 540 nm, so as to eliminate the effects of non-specific absorption.
A blank was carried out directly on the microtiter plates with the first column wells that contained all reagents except the MT-4 cells. All data represents the average values for a minimum of three wells. The 50% cytotoxic concentration (CC 50 ) was defined as the concentration of the compound that reduced the absorbance (OD 540 ) of the Mock-infected control sample by 50%. The percent protection achieved by the compounds in HIV-infected cells was calculated by the following formula:
(OD T ) HIV is the optical density measured with a given concentration of the test compound in HIV infected cells; (OD C ) mock is the optical density measured for the control untreated mock infected cells; all OD values determined at 540 nm. The dose achieving 50% protection according to the above formula was defined as the 50% effective concentration. Azidothymidine was used as standard. The anti-HIV activity data are presented in Table 2 . 
